Thermo Fisher Scientific Inc., has enrolled the first patient in the new PPD CorEvitas Alzheimer’s Disease Registry. Designed as an international, multi-country initiative, the registry is designed to generate robust, harmonized, fit-for-purpose real-world data under a common global protocol to support novel evaluations of drug safety and effectiveness that are critical for regulators, clinicians, patients and caregivers. Its longitudinal design, coupled with clinician-reported data from rout...